The Form 4 filing for Richard D. Francis was submitted on November 12, 2026, two days after the sale. Form 4 is an SEC report of an insider's stock trades and share ownership. He is president and CEO of Teva Pharmaceutical Industries Ltd. (TEVA).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-10 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 250,000 |
| Price | $42.24 |
| Total Transaction Value | $10,559,175.00 |
| Insider | |
| Ticker Symbol | TEVA |
| Company | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Insider Name | Francis Richard D |
| Insider Title | President and CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 927,529 |
| Position Size Change | 21.23% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with SEC transaction code S. It involved one transaction on November 10, 2026.
What was the average price of the transaction?
The average sale price was $42.2367 per share. Rounded to the nearest cent, that is $42.24.
How did this transaction affect the insider's holdings?
He sold 250,000 shares and reported 927,529 shares owned afterward. The sale covered 21.23% of the shares he held before the trade.
What's the total transaction value?
The total value was $10,559,175.00 for the single reported sale.
Are there any special circumstances around this transaction?
The available information identifies a reference to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. No footnote text or plan terms are available here, so it is unclear whether the reference covers this specific sale. The plan's start date and trading schedule are also unknown. The reference alone does not establish whether the trade met the rule's legal requirements or explain why he sold.
For research purposes only; not investment advice.